RESUMO
From an abscess of the submandibular gland, Salmonella typhimurium biotype 10 was isolated in pure culture. The patient had no history of gastroenteritis, and Salmonella could not be isolated from faeces.
Assuntos
Abscesso/microbiologia , Infecções por Salmonella/microbiologia , Salmonella typhimurium/isolamento & purificação , Doenças da Glândula Submandibular/microbiologia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
In a case of septicaemia, Aerococcus urinae was isolated from the blood. The patient had undergone operation on the prostate gland. The urine was sterile.
Assuntos
Bacteriemia/microbiologia , Infecções por Bactérias Gram-Positivas/microbiologia , Streptococcaceae/isolamento & purificação , Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Complicações Pós-Operatórias/microbiologia , Próstata/cirurgia , Especificidade da EspécieRESUMO
50% inhibitory concentration (IC50) and minimum inhibitory concentration (MIC) of ceftazidime, cefsulodin, cefotaxime, moxalactam, azlocillin, carbenicillin, netilmicin and tobramycin against 90 strains of Pseudomonas aeruginosa isolated from cystic fibrosis (CF) patients were determined by means of the agar plate dilution method. Ceftazidime was most active of the antibiotics in vitro; the geometric mean of IC50 was 0.2 and of MIC 0.4 micrograms/ml. 11 CF patients suffering from P. aeruginosa infection were treated with 14 day courses of ceftazidime (100 mg/kg/24 h) and tobramycin (10 mg/kg/24 h). P. aeruginosa was only temporarily eradicated in one of the patients, but a significant improvement of respiratory function and a significant fall in white blood cell count was recorded in the patients during chemotherapy. There was no development of resistant strains against ceftazidime during treatment and no side-effects were observed. Ceftazidime is a promising new antimicrobial agent with high in vitro activity which deserves further in vivo evaluation in CF patients.
Assuntos
Cefalosporinas/administração & dosagem , Fibrose Cística/complicações , Infecções por Pseudomonas/tratamento farmacológico , Tobramicina/administração & dosagem , Adolescente , Adulto , Ceftazidima , Cefalosporinas/farmacologia , Criança , Pré-Escolar , Doença Crônica , Quimioterapia Combinada , Humanos , Testes de Sensibilidade Microbiana , Infecções por Pseudomonas/diagnóstico , Pseudomonas aeruginosa/efeitos dos fármacos , Tobramicina/farmacologiaRESUMO
38 newborn infants, 28 males and 10 females, were treated with netilmicin in doses 6-7 mg/kg/day for suspected or verified infections. 19 patients were mature (mean birth weight 3169 g) and 19 were premature (mean birth weight 1864 g). 32 had moderate or severe underlying diseases. 37 babies survived, 33 were cured or improved markedly and in 4 the results were indeterminate. Pathogenic bacteria were demonstrated in 24 cases and were eliminated in 15. Only one baby died. He suffered from severe respiratory distress syndrome and Escherichia coli septicemia. No E. coli was isolated at autopsy. The mean netilmicin peak serum value was 7.7 micrograms/ml (range 1.0-30.0) and the mean trough concentration 2.1 micrograms/ml (range 0.0-9.2). No adverse effects were seen.
